text: <unk>  is a thrombopoietin receptor agonist that is FDA approved for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include thrombocytopenia, aplastic anemia, hyperbilirubinemia, fatigue, cough, epistaxis, fever, diarrhea.
option_0: Eltrombopag
option_1: Avatrombopag
option_2: Lusutrombopag
option_3: Reteplase
option_4: Otamixaban
option_5: Ximelagatran
option_6: Hirudin
option_7: Anistreplase